ZFYVE19

Across TCGA pan-cancer cohorts, ZFYVE19 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZFYVE19 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZFYVE19 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZFYVE19 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

LUAD, HNSC, and COAD are the cancer types where ZFYVE19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.696	0.961	<.001	43	view →
HNSC	DFS	Median	III,IV	0.484	0.744	.003	26	view →
COAD	DFS	Median	All	0.920	1.000	.014	24	view →
UCEC	OS	Tertile	All	1.000	0.913	.039	4	view →
PDAC	OS	Median	All	0.915	0.750	.026	4	view →
CCRCC	DFS	Tertile	II,III,IV	0.915	0.399	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZFYVE19–LUAD (DFS)

Open the LUAD breakdown →